The drug met its primary endpoints in a Chinese trial, while a Phase III trial in Sjögren's syndrome is currently underway in ...

While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune ...

China-based RemeGen has announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, ...

On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...

Good news in research for Novartis. The pharmaceutical giant has achieved the hoped-for results for Ianalumab, a candidate ...

Vor Bio shares climb as RemeGen's Phase 3 study in China shows telitacicept improves disease activity in primary Sjögren's ...

Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a Phase 3 study titled ‘A Phase 3 Randomized, ...

World No. 1 Jannik Sinner has yet to drop a set at the Cincinnati Open heading into the quarterfinals. Sinner will face Felix ...

Venus Williams is back on the professional tennis tour at age 45 and will be returning to the U.S. Open next week for her ...

Adults with Sjögren’s disease complicated by a subtype of cutaneous vasculitis are more likely to develop non-Hodgkin’s ...